yuankai shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
17
15
4
N/A
0
6
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+14 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (17)
Showing 10 of 17 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Shoubin Wen, MD
Sound Biopharmaceuticals Ltd.
Shared therapeutic areas:
Worked with same sponsors:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Worked with same sponsors:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (17)
Showing 17 of 17 trials
Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation
Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
All 17 trials loaded